Sanofi announced the appointment of Dr. Gary J. Nabel, M.D., Ph.D., to Chairman of the Strategic Development and Scientific Advisory Council (SDSAC). Dr. Nabel, currently Senior Vice President, Chief Scientific Officer and Deputy to Dr. Elias Zerhouni, President, Global R&D, will succeed Dr. Richard Klausner. As part of his key responsibilities as Chief Scientific Officer for global R&D, Dr. Nabel will direct the activities of the Council, including selection, appointment and evaluation of advisers.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
92.02 EUR | +0.11% |
|
-1.64% | +2.52% |
07-17 | Sanofi to invest $437 million in India global centre, double its workforce | RE |
07-17 | EU court criticizes Commission over handling of COVID vaccine contracts | RE |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+2.52% | 125B | |
+55.35% | 848B | |
+31.64% | 627B | |
-0.10% | 363B | |
+15.47% | 318B | |
+13.10% | 299B | |
+15.51% | 243B | |
+16.72% | 225B | |
+16.54% | 179B | |
+4.31% | 167B |
- Stock Market
- Equities
- SAN Stock
- News Sanofi
- Sanofi Announces Executive Changes